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Iron and copper are important co-factors for a number of enzymes in the brain, including
enzymes involved in neurotransmitter synthesis and myelin formation. Both shortage and
an excess of iron or copper will affect the brain. The transport of iron and copper into the
brain from the circulation is strictly regulated, and concordantly protective barriers, i.e., the
blood-brain barrier (BBB) and the blood-cerebrospinal fluid (CSF) barrier (BCB) have evolved
to separate the brain environment from the circulation.The uptake mechanisms of the two
metals interact. Both iron deficiency and overload lead to altered copper homeostasis in
the brain. Similarly, changes in dietary copper affect the brain iron homeostasis. Moreover,
the uptake routes of iron and copper overlap each other which affect the interplay between
the concentrations of the two metals in the brain.The divalent metal transporter-1 (DMT1)
is involved in the uptake of both iron and copper. Furthermore, copper is an essential co-
factor in numerous proteins that are vital for iron homeostasis and affects the binding of
iron-response proteins to iron-response elements in the mRNA of the transferrin receptor,
DMT1, and ferroportin, all highly involved in iron transport. Iron and copper are mainly taken
up at the BBB, but the BCB also plays a vital role in the homeostasis of the two metals, in
terms of sequestering, uptake, and efflux of iron and copper from the brain. Inside the brain,
iron and copper are taken up by neurons and glia cells that express various transporters.
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INTRODUCTION
The transition metals, iron and copper are co-factors for a vari-
ety of proteins that are vital for the normal function of cells. In
the brain, iron and copper are important co-factors for enzymes
involved in, e.g., neurotransmitter synthesis and myelin formation
(Gaggelli et al., 2006; Lutsenko et al., 2010). When in excess, they
both participate in the Fenton reaction – a series of chemical reac-
tions initiated by transition metals and hydrogen peroxide – which
leads to the formation of unstable free radicals that significantly
affect DNA, proteins, and lipids and cause deleterious damage
to the cells (Rivera-Mancia et al., 2010). Therefore a strict reg-
ulation of these metals is vital for normal cellular function and
survival.
In biological systems, iron mainly exists in two ionic forms, i.e.,
ferrous iron (Fe2+) and ferric iron (Fe3+). Outside the cell, iron
is in its oxidized, almost insoluble Fe3+ state and is virtually com-
pletely bound to the liver-derived protein transferrin (Table 1).
Intracellularly, iron mainly occurs as Fe2+. Most inorganic iron in
the diet is in the Fe3+ form and must be reduced to Fe2+ before
Abbreviations: APP, amyloid precursor protein; BBB, blood-brain barrier; BCB,
blood-CSF barrier; CSF, cerebrospinal fluid; Ctr1, copper transporter-1; Cu, cop-
per; DMT1, divalent metal transporter-1; Fe, iron; Fe2+, ferrous iron; Fe3+, ferric
iron; GSH, glutathione; IRE, iron-response element; IRP, iron-regulatory protein;
MT, metallothionein; NMDA, N -methyl d-aspartate; P, postnatal.
it can be taken up by the divalent metal transporter-1 (DMT1)
which is located in the apical membrane of gastrointestinal cells.
This reduction is probably facilitated by duodenal cytochrome
b, DcytB (McKie et al., 2001), and possibly other reductases like
Steap2, which is abundantly expressed in the duodenum and local-
izes to the cell membrane (Ohgami et al., 2006). Also heme-bound
iron enters enterocytes but by a mechanism that does not involve
DMT1. The heme carrier protein 1 (HCP-1) is a likely candidate for
heme-iron uptake in the intestine (Shayeghi et al., 2005; Latunde-
Dada et al., 2006). Cellular heme-iron uptake is followed by heme-
oxygenase-mediated degradation of heme and the release of Fe2+
(West and Oates, 2008). Fe2+ from either route is subsequently
transported through the enterocytes by unknown mechanisms to
the basolateral membrane to where it is probably exported to the
circulation by ferroportin in conjunction with being reoxidized to
Fe3+ by the copper-containing protein, hephestin (Frazer et al.,
2001; Anderson et al., 2002). In the circulation, the iron binds to
the liver-derived transferrin (apotransferrin) which is the main
ferric iron-binding protein in plasma. Under normal physiolog-
ical conditions, there is virtually no non-transferrin bound iron
in the circulation, as the iron-binding capacity of transferrin is
far from saturated. Transferrin bound iron in the blood plasma is
taken up by cells that express transferrin receptor 1 located on the
cell membrane followed by clathrin-mediated endocytosis (Moos
and Morgan, 1998; Levy et al., 1999).
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Table 1 |Transporters involved in transport of iron and copper, respectively, in different cell types.
Ionic forms Transport in
intestine
Transport
in the
circulation
Transport in
peripheral
cells
Transport
across
the BBB
Transport
across
the BCB
Transport in
neurons
Transport in
astrocytes
IRON
Fe2+ (intracellularly) DMT1 (Mem) Transferrin TfR TfR TfR TfR DMT1 (Mem)
Fe3+ (extra-cellularly) Ferroportin+HP DMT1 (End) DMT1 (End) DMT1 (End) Ferritin
Haem-iron:
HCP-1, not
involving DMT1
Ferritin DMT1 (Mem) Ferritin Ferroportin
+GPI- anchored CP
Ferroportin+CP Ferroportin+HP Ferroportin
+CP+HP
(No TfR expression)
COPPER
Cu+ (intracellularly) Ctr1 CP Ctr1 Ctr1 Ctr1 Ctr1 Ctr1
Cu2+ (extra-celullarly) DMT1 (Mem) Albumin ATOX1 ATOX1 DMT1 (Mem) ATOX1 ATOX1
ATP7A ATP7A/ATP7B ATP7A ATOX1 ATP7A ATP7A
ATP7A ATP7B
ATP7B
DMT1 (Mem), DMT1 located in the cell membrane; DMT1 (End), DMT1 located in endosomes; CP, ceruloplasmin; HP, hephestin;TfR, transferrin receptor. Underlined
text represents molecules of interaction between iron and copper metabolism. See text for further details.
Copper is also a redox-active transition metal which read-
ily changes its oxidation state between Cu+ and Cu2+ (Sharp,
2004). Outside the cell, copper mainly appears as Cu2+, and
intracellularly mainly as Cu+. The uptake of dietary copper in
intestinal epithelial cells is carried out by the high-affinity copper
transporter-1 (Ctr1) located apically in the plasma membrane.
Prior to its import to the cell, the Cu2+ is reduced to Cu+. The
reductase involved in this process is not yet identified, but it has
been demonstrated that members of the Steap family are able
to perform this reduction in cell cultures (Ohgami et al., 2006).
DMT1 might also be involved in the transport of copper ions
into enterocytes (Arredondo et al., 2003; Sharp, 2004), although
the statement was recently questioned (Illing et al., 2012). Several
in vitro studies have shown that DMT1 can transport copper in
Caco-2 cells (Arredondo et al., 2003; Espinoza et al., 2012), but the
significance of DMT1 for intestinal copper uptake in vivo remains
to be established. However, DMT1 seems to be involved in copper
metabolism in vivo as shown in the Belgrade rat, which carries a
mutation in DMT1. The iron-deficient Belgrade rat is not com-
promised in copper status, which is in contrast to iron-deficient
wild type rats, which show an increase in serum and hepatic cop-
per levels (Jiang et al., 2011). This result indicates that DMT1 is to
some extent involved in copper metabolism.
In contrast to iron, it is also possible that copper gets trans-
ported through enterocytes by passive diffusion (Varada et al.,
1993). Inside cells, copper is bound to one of several copper chap-
erones (CCS, Cox17, Cox11, ScoI, ScoII, ATOX1; Huffman and
O’Halloran, 2001; Puig and Thiele, 2002; Madsen and Gitlin, 2007;
Lutsenko et al., 2010) or to storage and ligand molecules like metal-
lothionein (MT) and glutathione (GSH), respectively. The P-type
ATPase ATP7A mediates the basolateral release of copper from
the enterocyte into the circulation. The copper chaperone ATOX1
is involved in the transport of copper to ATP7A inside the cell.
In blood plasma, copper is mainly bound to ceruloplasmin, but
also for instance to albumin (Table 1). Copper is then transported
from the circulation into cells in its Cu+-form by Ctr1 in similar-
ity with the transport into the intestinal epithelial cells, described
above (Lee et al., 2002). Upon entering cells from the circulation
the copper is – like in the enterocytes – bound to chaperones and
storage molecules. Similarly to iron, the cytosolic concentration
of unbound copper is very low (Rae et al., 1999; Huffman and
O’Halloran, 2001).
The transport of molecules from the circulation into the brain
is strictly regulated, and is hindered by the protective barriers that
separate the brain environment from the circulation (Figure 1).
The blood-brain barrier (BBB) separates the blood circulation
from the brain interstitial fluid, and the blood-cerebrospinal fluid
(CSF) barrier (BCB) separates the blood from the CSF. The
BBB consists of brain capillary endothelial cells that – in con-
trast to peripheral endothelial cells – are intimately connected by
tight junctions and are non-fenestrated. Astrocytes and pericytes
also contribute to the formation and maintenance of the BBB.
The brain capillary endothelial cells are not uniform throughout
the brain, as capillaries in the circumventricular organs and the
choroid plexus contain fenestrated endothelial cells. The blood-
CSF barrier is located between the blood and the choroid plexus.
The epithelium of the choroid plexus is polarized with the baso-
lateral side facing the blood, whereas the apical part contains
microvilli that are in direct contact with the CSF. All solutes
are transported through the blood-brain and blood-CSF barri-
ers to the brain interstitial fluid and CSF, respectively. The cells
denoting these barriers transport essential nutrients, metals, and
pharmaceuticals into the brain in a controlled manner (Begley and
Brightman, 2003; Abbott et al., 2006).
This review addresses the uptake and transport of iron and
copper in the brain and discusses how these essential metals may
play a role in the pathogenesis of brain diseases via their absence
or their gradual accumulation due to hereditary or environmental
dietary events. As the regulation of iron and copper transport in
the brain strongly interact with each other, a separate section is
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FIGURE 1 | Schematic presentation of the localization of the BBB and
the BCB. White cells are capillary endothelial cells. Blue cells are
ependymal cells. The structure of cell layers in the choroid plexus/BCB is
shown in the top of the figure. The structure of cell layers elsewhere in the
brain/BBB is shown in the lower part of the figure. The capillary endothelial
cells are tightly bound by tight junctions, except at the choroid plexus. In
the choroid plexus the ependymal cells are, in contrast to elsewhere in the
brain, tightly bound by tight junctions.
devoted to how any imbalance of iron and copper homeostasis
in the brain may affect their inter-relations and eventually affect
neuronal functions.
REGULATION
The expression and activity of iron and copper transporters are
regulated at different levels. Most iron transporters are regulated
in response to iron levels in the cell by binding iron-regulatory
protein 1 or 2 (herein collectively referred to as iron responsive
proteins, IRPs) to the iron-response element (IRE) located in the
UTR regions of the mRNA of these transporters. At high iron
concentrations the IRPs binds iron, which changes the conforma-
tion or stability of IRPs and makes them unsuitable for binding to
IRE. Ferroportin and ferritin have an IRE element in the 5′UTR
of their mRNA, whereas the IRE element is located in the 3′UTR
of the mRNA of the transferrin receptor and DMT1. Only two of
four DMT1 isoforms have an IRE element. The binding of IRP
to ferroportin and ferritin mRNAs mediates a repression of their
translation, whereas the binding of IRP protects the mRNA of
transferrin receptor and DMT1 from degradation (Wang and Pan-
topoulos, 2011). Furthermore, ferroportin expression is regulated
by circulating hepcidin which induces its internalization (Nemeth
et al., 2004). Hepcidin is also suggested to regulate DMT1 expres-
sion as DMT1 mRNA levels decrease in Caco-2 cells cultured in
hepcidin-conditioned medium (Mena et al., 2006).
The general expression level of copper transporters occur inde-
pendently of the cellular copper levels, however the subcellular
localization of many transporters are affected by the copper state
of the cells. Hence, at steady state levels, Ctr1 constitutively cycles
between the plasma membrane and intracellular compartments,
whereas at high concentrations Ctr1 is internalized at the cellu-
lar membrane and subsequently degraded (Petris et al., 2003). At
steady state levels, ATP7A and ATP7B are mainly localized in the
trans-Golgi network where they are responsible for incorporating
copper into Cu-proenzymes. At high copper concentrations, the
two proteins distribute to post-Golgi vesicles and even to the cel-
lular membrane in order to facilitate the export of copper from the
cell. The relocalization of ATP7A and ATP7B is reversible and does
not requiredenovo protein synthesis (Petris et al., 1996; Hung et al.,
1997; Roelofsen et al., 2000; van den Berghe and Klomp, 2010).
IRON TRANSPORT AND HOMEOSTASIS IN THE BRAIN
Like most other cell types, brain capillary endothelial cells take
up iron by binding holotransferrin to the transferrin receptor, fol-
lowed by endocytosis of the holotransferrin-transferrin receptor
complex (Moos and Morgan, 1998; Levy et al., 1999). In other cell
types, Fe3+ is detached from the receptor-ligand complex within
the endosome, is reduced to Fe2+, and is pumped out into the
cytosol by DMT1. Subsequently, the iron concentration is instantly
regulated by three different processes, (1) the incorporation into
organic molecules in its ferrous form, (2) storage as ferritin-
iron subsequent to its re-oxidization, or (3) ferroportin-mediated
export from the cell. However, presumably neither DMT1 nor
ferroportin are expressed in brain capillary endothelial cells as
demonstrated by protein blotting, immunohistochemistry and
in situ hybridization on brains from adult rats and mice, or from
iron-deficient rats (Gunshin et al., 1997; Moos and Morgan, 2004;
Moos et al., 2006; Rouault et al., 2009). Notably, some controversy
exist on the expression of DMT1 and ferroportin in brain capillary
endothelial cells (Burdo et al., 2001; Yang et al., 2011; McCarthy
and Kosman, 2012).
Hence, presumably a different route from the one normally
employed during holotransferrin-mediated uptake could occur at
the BBB. One hypothesis is that iron is transcytosed through the
cells with little or no iron being pumped out of the trafficking
vesicles into the cytosol (Moos et al., 2007; Figure 2). Instead,
the vesicle carrying the transferrin-iron complex may dock at the
abluminal surface of the brain capillary endothelial cell where the
complex is subjected to the local factors of the microenvironment
such as ATP,nucleotides and citrate secreted from astrocytes,which
circumscribe the abluminal part of brain capillary endothelial
cells, leading to iron release (Morgan, 1977, 1979). The iron-
free apotransferrin, which is not released from the transferrin
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FIGURE 2 | Proposed model for iron and copper transport across the
BBB. The mechanisms are described in the text.
receptor during the transcellular transfer, is recycled inside trans-
ferrin receptor-containing endosomes to the luminal side of the
brain capillary endothelial cells, from where it is returned to the
circulation (Moos and Morgan, 2004).
The uptake-level of iron by the brain remains very constant,
unless the concentration of iron in the brain is reduced. Should
that happen, receptor internalization by brain capillary endothelial
cells is significantly elevated resulting in an increased extraction
of iron from blood plasma and transport into the brain (Mon-
not et al., 2011). Conversely, if iron levels in the blood plasma are
raised, the brain capillary endothelial cells cease to take up iron
(Morgan, 1996). In turn, these operating mechanisms at the BBB
strongly protect the brain from being affected by fluctuations in
systemic iron, and any disturbance of systemic iron homeostasis
will have minimal effect on the iron levels in the CNS (Moos and
Morgan, 2004).
Inside the brain, iron is taken up by neurons and glia cells by
putatively different mechanisms. A recent study demonstrated that
neurons in primary culture do not take up non-transferrin bound
iron by a mechanism that involves binding to DMT1 (Pelizzoni
et al., 2012). Neurons contain transferrin receptors and DMT1
located in endosomes, and most likely acquire iron by classi-
cal holotransferrin internalization followed by DMT1-mediated
pumping of iron into the cytosol. In contrast, astrocytes and oligo-
dendrocytes are likely to take up non-transferrin bound iron as
they are devoid of transferrin receptors, even at substantial iron
deficiency levels, where neurons increase their expression of trans-
ferrin receptors significantly (Moos et al., 1998). There are at least
two distinct routes for uptake of non-transferrin bound iron in
astrocytes, and one of these is DMT1-independent (Lane et al.,
2010). The details of these routes are unknown. However, the
metal transporters Zip 8 and Zip 14 may be involved as they
have been shown to transport several divalent metal ions includ-
ing iron (Fe2+) but not copper-ions (Pinilla-Tenas et al., 2011;
Jenkitkasemwong et al., 2012). mRNA from both Zip 8 and Zip
14 has been identified in tissue from mouse brain (Girijashanker
et al., 2008).
Judging from the rather heterogeneous distribution of ferritin
in the brain, residual iron is stored in neurons and some glial
cell types (Benkovic and Connor, 1993). Hence, some neuronal
nuclei, e.g., hippocampal, hypothalamic, and mesencephalic neu-
rons express ferritin, whereas a number of neuronal nuclei are
devoid of ferritin-containing neurons (Hansen et al., 1999).This is
however not true for the aged brain in which neuronal iron and fer-
ritin levels increase (Benkovic and Connor, 1993). Non-neuronal
cells, in particular microglia and oligodendrocytes, also increase
their content of iron and subsequently express more ferritin with
age (Benkovic and Connor, 1993).
Extracellular iron in the brain is supposedly handled via its
binding to transferrin and low-molecular weight substances like
ATP, nucleotides and citrate. Extracellular transferrin is quite
scarce in the brain and is mainly derived from synthesis and secre-
tion by the choroid plexus and transcytosis of liver-derived trans-
ferrin at the choroid plexus (Moos et al., 2007; Rouault et al., 2009).
Furthermore, the choroid plexus epithelial cells play a role in brain
iron homeostasis, which is supported by the expression analyses
that demonstrated the presence of various iron transporters such
as transferrin receptor, DMT1, and ferroportin (Rouault et al.,
2009; Figure 3). The relative contribution to the total iron trans-
port into the brain mediated by the choroid plexus is however
difficult to determine. Theoretically its contribution could be sub-
stantial, as the surface area of the choroid plexuses is at least half
the area of the BBB (Keep and Jones, 1990), and the regional blood
flow through their capillaries is approximately fivefold higher
compared to many other regions in the brain (Maktabi et al.,
1990). The choroid plexus epithelial cells have apical microvilli,
suggesting that these cells play an absorptive role, which might be
involved in iron transport from the CSF to the blood. This the-
ory is supported by a study of rat primary choroid epithelial cells
in a two-chambered Transwell system (Wang et al., 2008), where
free iron was transported across the cells from the apical to the
basolateral side. Apically located DMT1 played a major role in this
process. The iron-transporting proteins expressed by the choroid
plexus might also play a significant role in managing cellular iron
utilized by the epithelial cells themselves.
COPPER TRANSPORT AND HOMEOSTASIS IN THE BRAIN
The concentration of copper in the brain is higher than in other
organs except for the liver (Lech and Sadlik, 2007). The level of
copper uptake varies in different regions of the brain, e.g., copper
uptake is significantly higher in the hippocampus than in the cere-
bellum (Choi and Zheng, 2009). This may reflect differences in
regional blood flow, capillary density, or the abundance of copper
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FIGURE 3 | Proposed model for iron and copper transport across the
BCB. The mechanisms are described in the text.
transporter expression. The bulk of copper transport into the brain
is thought to occur at the BBB, but the choroid plexus is also capa-
ble of transporting copper (Monnot et al., 2011; Figures 2 and 3).
Using choroid epithelial cells, Z310, as an in vitro model of the
BCB, siRNA specifically targeting the mRNAs of Ctr1, DMT1,
ATOX1, and ATP7A respectively revealed that all of these proteins
presumably are involved in copper transport across the choroid
plexus (Monnot et al., 2012).
It is believed that copper is transported into the brain as a free
ion. Using the brain perfusion technique, it was shown that the
uptake of free copper (CuCl2) into brain capillaries, the choroid
plexus and the CSF is much higher than the uptake of Cu-albumin
or Cu-ceruloplasmin. The highest uptake from the blood was
observed in the choroid plexus (Choi and Zheng, 2009). However,
the further transport of copper into the CSF was almost 1200-fold
slower, indicating that the choroid plexus sequesters the metal and
strictly regulates its further movement into the brain (Choi and
Zheng, 2009).
Whereas DMT1 presumably is absent from the brain capillary
endothelial cells, there is plenty of Ctr1 which is assumed to play
an important role in copper transport from the blood into the
brain across the brain capillary endothelial cells. This notion is
supported by studies on the Ctr1+/− mouse, which – when com-
pared to controls – has an approximately 50% lower expression of
Ctr1 and a concurrent 50% lower copper transport level into the
brain (Lee et al., 2001). Ctr1 is also widely expressed in the choroid
plexus, and even more than in the brain capillary endothelial cells.
Furthermore, the amount of Ctr1 is increased in the choroid plexus
in copper-deficient mice (Kuo et al., 2006). The Ctr1 on the apical
surface of the choroid plexus epithelial cells is believed to play an
important role in copper transport from the CSF out of the brain.
ATP7A has been shown to facilitate copper transport across
brain endothelial cells in vitro, and is essential for transporting cop-
per further into the brain (Qian et al., 1998). This fits well with the
fact that the brindled mutant mouse (a mouse model for Menkes
disease) with a mutated ATP7A gene, has a higher than normal
copper accumulation in brain capillaries combined with copper
deficiency in the brain (Yoshimura et al., 1995). The related P-type
ATPase ATP7B is also expressed in the brain, but not in brain cap-
illary endothelial cells, and is therefore not believed to play a major
role in copper transport into the brain (Qian et al., 1998; Barnes
et al., 2005). ATP7B is however expressed in the choroid plexus,
although at 14-fold lower levels than those of ATP7A (Choudhuri
et al., 2003). Characteristically, ATP7B traffics to sub-luminal vesi-
cles, but not to basolateral membranes, and is presumably involved
in copper transport from the blood to the CSF.
Inside the brain, copper is utilized by a large number of impor-
tant neuronal enzymes such as cytochrome c oxidase, Cu, Zn –
dependent superoxide dismutase, peptidylglycine alpha amidating
monooxygenase, dopamine beta monooxygenase, tyrosinase, and
lysyl oxidase (Lutsenko et al., 2010). Furthermore, copper exerts
antagonistic-like action on glutamatergic N -methyl d-aspartate
(NMDA) receptors. In cultured hippocampal neurons, addition
of copper leads to a rapid and reversible trafficking of ATP7A to
neuronal processes regardless of the intracellular copper concen-
tration. The copper acts specifically on NMDA receptors and leads
to a rapid release of copper from the hippocampal neurons (Schlief
and Gitlin, 2006). In contrast, a simultaneous activation of NMDA
receptors does not lead to release, but to an enhanced uptake of
ferrous iron in cell cultures (Cheah et al., 2006).
Metallothionein is strongly expressed in choroid plexus epithe-
lial cells, suggesting that these cells serve as a reservoir for copper
(Penkowa et al., 1999). An in vitro two-chamber model of the BCB
revealed that the choroid plexus epithelial cells may play a key role
in copper homeostasis in the brain by expelling copper from the
CSF to the blood side; the main direction of the copper transport
went from the apical side to the basolateral side of the epithelial
cells (Monnot et al., 2011). Interestingly, the choroid plexus exhib-
ited the highest capacity for copper uptake from the blood when
compared to brain capillaries, brain parenchyma, and CSF in vivo.
The transport is however 1200-fold slower from the choroid plexus
into the CSF (Choi and Zheng, 2009). Thus, the blood-CSF bar-
rier might play a considerable role in the regulation of copper by
maintaining copper at a certain level, by sequestering copper from
the blood and exporting excess copper out of the CNS back to the
blood.
IRON-RELATED NEURONAL PATHOLOGIES
Characteristically for transition metals such as iron and copper,
both their absence and excess affect organs throughout the body,
including the brain.
Deficiency in iron mediates changes in the expression of a
number of iron-related genes and their resulting proteins in the
brain leading to, e.g., a rise in neuronal transferrin receptors and a
decrease in neuronal ferritin, whereas the accumulation of iron by
the brain reverses their expression (Hansen et al., 1999). Brain iron
accumulation occurs in many chronic neurodegenerative diseases
like Parkinson’s disease and Huntington’s disease. Excess iron is
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also found in the brain of patients with rare mutational diseases,
where genes involved in the management of iron are affected.
BRAIN PATHOLOGY RESULTING FROM DEFICIENCY IN BRAIN IRON
Iron deficiency in the brain leads to hypomyelination (Beard and
Connor, 2003), abnormal cognition, changes in neurotransmit-
ter metabolism, and impaired motor function (Kwik-Uribe et al.,
2000a; Grantham-McGregor and Ani, 2001; Beard et al., 2006). If
the iron deficiency occurs during early development, lifelong cog-
nitive and motor impairment are observed in both rodents and
humans (Kwik-Uribe et al., 2000a; Siddappa et al., 2004; DeBoer
et al., 2005; Carlson et al., 2009). These impairments persists
even after a complete iron repletion (Felt and Lozoff, 1996; Kwik-
Uribe et al., 2000b; DeBoer et al., 2005; Felt et al., 2006; Lozoff
et al., 2006). The adverse effects affect both brain morphology and
development. For instance the Slc11a2hipp/hipp mouse, which has
a conditional knock-out in the DMT1 gene in the hippocampus
that results in regional iron deficiency, had abnormal hippocampal
morphology and slower learning abilities (Carlson et al., 2009). A
different rodent model showed that iron deficiency anemia during
gestation and early postnatal life was accompanied by an altered
expression of genes involved in the regulation of synaptic activity
and apical dendritic growth in the hippocampus (Jorgenson et al.,
2003, 2005).
Postnatal P15 (P) rats with neonatal iron deficiency exhib-
ited an altered expression in six of seven genes implicated in
Alzheimer’s disease pathogenesis (Carlson et al., 2008). The same
seven genes were upregulated in the Slc11a2hipp/hipp mouse from
P5 to P25, but returned to normal levels by P25 (Carlson et al.,
2008). An upregulation of these genes during development may
however lead to a higher expression again in adulthood. This phe-
nomenon was observed in another study (Basha et al., 2005) where
the upregulation of the β-amyloid protein precursor (app) gene –
one of the tested Alzheimer’s disease genes – was observed in the
cortex of P15 rats after exposure to lead during the early postna-
tal period. Although the expression of app returned to normal in
early adulthood, the increased expression was reactivated in senes-
cence without re-exposure to the toxin. Hence, a deregulation of
expression during development due to brain iron deficiency may
affect gene expression and pathology later in life.
INHERENT HUMAN DISEASES ACCOMPANIED BY BRAIN PATHOLOGY
AND IRON ACCUMULATION
Iron accumulation is directly involved in the brain pathology of
some inherent diseases that directly affects the cellular handling of
iron by neurons. One example is neuroferritinopathy, which is an
autosomal dominant disease that results in extrapyramidal symp-
toms due to mutation in the gene encoding the ferritin light (L)
chain (Dusek et al., 2012; Keogh et al., 2012). Ferritin is an iron
storage complex composed of 24 protein subunits consisting of
heavy (H) chains and light (L) chains. The L-chains are dominant
in ferritin in organs that store iron, where it is responsible for iron
nucleation into the safe ferric state. The H-chains are dominant in
ferritin in organs with a high iron metabolism (Koziorowski et al.,
2007). The composition of the two subunits in ferritin is impli-
cated in keeping the balance between bound and labile iron. In the
brain, neurons mostly contain H-rich ferritin, whereas microglia
mostly contain L-rich ferritin (Connor et al., 1994). Patients with
neuroferritinopathy have abundant iron accumulation in the brain
and neuronal loss that causes involuntary movements, dystonia,
spasticity, and rigidity. However, the patients display no systemic
abnormality, except for a decreased level of serum ferritin (Curtis
et al., 2001). It has been suggested that the mutations in L-ferritin
impair the ferritin assembly and result in a loss of iron storage
capacity within brain cells and a subsequent iron-mediated cell
injury (Levi et al., 2005).
Another example is panthothenate kinase-associated neurode-
generation (PKAN; formerly Hallervorden–Spatz disease), which
is characterized by excessive iron accumulation in the brain accom-
panied by neuronal loss (Zhou et al., 2001). The accumulation of
iron in PKAN is thought to be secondary to a mutation in the gene
encoding the enzyme pantothenate kinase 2. This mutation leads
to the accumulation of cysteine residues that – because of their
high-affinity for divalent metal ions – may cause accumulation of
iron in neurons (Zhou et al., 2001).
A more recently identified mutation in the PLA2G6 gene that
encodes a calcium-independent phospholipase A2 [iPLA(2)beta]
also leads to progressive iron accumulation in the brain accompa-
nied by neuronal dystrophy and cell loss (Gregory et al., 2008).
Deletion of the gene in an experimental model leads to an
iPLA(2)beta-loss-of-function, to severe neuronal dystrophy, and
to brain iron accumulation (Malik et al., 2008).
IRON ACCUMULATION IN NEURODEGENERATIVE DISEASES
Iron accumulates in brains of patients with Parkinson’s disease
(Dexter et al., 1989, 1991). Similar observations have been made
in patients suffering from other neurodegenerative diseases, e.g.,
Alzheimer’s disease and Huntington’s disease (Moos and Mor-
gan, 2004). However, the association between iron accumulation
and neurodegeneration has received most attention in an attempt
to explain iron’s contribution to the pathogenesis of Parkinson’s
disease. Experimental studies have confirmed that chronic degen-
eration in the brain is accompanied by the accumulation of iron
(Sastry and Arendash, 1995). Although there is a clear indication
that iron plays a significant role in neuronal cell death in patients
suffering from neurodegenerative diseases, a direct connection
to iron accumulation in the relevant brain regions has never
been demonstrated directly. However, data from patients with
hemochromatosis clearly indicate that iron deposition in non-
neuronal organs is harmful to cells and leads to disease (Rouault,
2001). Experimental studies on cultured neurons have also pro-
vided evidence that iron damages neurons in a dose-responsive
manner (Ostrerova-Golts et al., 2000), hence clearly suggesting
that the exposure to excess iron is harmful to neurons. Apart from
the directly intoxicated neurons, iron can propagate an oligomer-
formation of alpha synuclein that leads to a gradual intoxication
of alpha synuclein-containing aggregates.
Parkinson’s disease occurs as a result of dopaminergic neuronal
death in the substantia nigra pars compacta. Excess labile iron that
can participate in the Fenton reaction, is thought to contribute
heavily to oxidative stress and subsequent degeneration among
dopaminergic neurons (Halliwell, 1992). Many Parkinson’s dis-
ease patients have an – as yet unexplained – increased level of
total iron in the substantia nigra as compared to age-matched
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controls (Sofic et al., 1988; Dexter et al., 1991; Griffiths and Cross-
man, 1993). The (+IRE) isoforms of DMT1 has been shown to be
upregulated in Parkinson’s disease patients (Salazar et al., 2008).
DMT1 may play a critical role in iron accumulation and in the
pathogenesis of Parkinson’s disease as macrocytic mice (mk/mk)
and Belgrade rats, which carry the same mutation in DMT1 that
impairs iron export, are partially protected against parkinsonism-
inducing neurotoxins (Salazar et al., 2008). Interestingly Parkin,
a protein component of a multiprotein E3 ubiquitin ligase com-
plex, which in its mutated form cause autosomal recessive juvenile
Parkinson’s disease, is a regulator of expression of the 1B iso-
forms of DMT1 (Roth et al., 2010). Furthermore, iron could
accumulate in neurons because of their decreasing ability to reuse
the iron, thereby leading to their higher need for iron uptake
(Moos et al., 2007). A decreasing ferroxidase activity mediated
by ceruloplasmin in the Parkinson’s disease brain could result in a
lower capacity for cellular iron export (Olivieri et al., 2011). Like-
wise, iron accumulation may also originate from iron-containing
monocytes and macrophages that continuously migrate into the
affected substantia nigra.
It should also be mentioned that the increase in brain iron does
not always apply to Parkinson’s disease patients (Uitti et al., 1989;
Galazka-Friedman et al., 1996; Loeffler et al., 1996). This could be
due to the fact that the pool of labile iron stored in ferritin – and
therefore available for the Fenton reaction – may vary, and may
evoke oxidative damage in neurons even though the level of total
iron is not raised. Several studies have demonstrated a decreased
level of L-chain-ferritin in the substantia nigra of Parkinson’s dis-
ease patients compared to that of controls (Connor et al., 1994;
Koziorowski et al., 2007). This decreased level could lead to an
increased efflux of iron from the ferritin complex into the remain-
ing cytosol as described in patients with neuroferritinopathy (see
above), which in turn could lead to higher levels of free labile iron.
Concurrently, a statistically significant twofold higher reactive oxy-
gen species (ROS) activity was seen in substantia nigra tissue of
Parkinson’s disease patients as compared to controls, notably with-
out differences in total iron in the substantia nigra between the two
groups (Wypijewska et al., 2010). Also ferritin accumulation has
been reported in some – but not all – Parkinson’s disease patients
(Dexter et al., 1991; Connor et al., 1995; Faucheux et al., 2002; Bart-
zokis et al., 2004). Chronic ferritin elevation has been shown to
result in progressive age-related neurodegeneration of midbrain
dopamine containing neurons (Kaur et al., 2007). Thus several
paths may lead to the same result of iron mediated oxidative stress
in Parkinson’s disease.
Alzheimer’s disease is accompanied by accumulation of iron
in addition to zinc in β-amyloid (Aβ) – containing plaques. The
aggregation of Aβ is induced by Zn2+. Aβ is derived from the amy-
loid protein precursor protein APP, which has recently been shown
to be able to catalyze the binding of iron with transferrin and to
interact with ferroportin (Duce et al., 2010). APP null (app−/−)
mice suffer from iron accumulation and oxidative stress in cor-
tical neurons, and accumulation of iron is comparable with that
occurring in astrocytes in ceruloplasmin null (cp −/−) mice. Zink-
ions (Zn2+) inhibit the ferroxidase activity of APP and abnormal
exchange of cortical zinc may link APP to iron accumulation in
Alzheimer’s disease (Duce et al., 2010).
COPPER-RELATED NEURONAL PATHOLOGIES
Copper is essential for normal CNS function. It is required as co-
factor for dopamine beta monooxygenase, peptidylglycine alpha
amidating monooxygenase, superoxide dismutase, and a large
number of other enzymes. Furthermore it is required for mito-
chondrial respiration and oxidation of Fe2+ leaving the brain
vulnerable in case it gets deprived in copper. On the other hand
too much copper is toxic. Brain copper accumulation observed in
Wilson disease results in parkinsonian symptoms such as dystonia
and dysarthria.
IMPACT OF DEVELOPMENTAL COPPER-DEFICIENCIES ON BRAIN
FUNCTION
An interrupted copper homeostasis in the brain has severe
effects. For instance, cerebral copper deficiency is associated with
decreased neuronal cytochrome c oxidase activity that conse-
quently alters mitochondrial function and brain energy metabo-
lism (Gallagher et al., 1956). The development of the brain is also
likely to become affected due to a decreased amount of dopamine-
β-monooxygenase which leads to a lower level of noradrenaline
synthesis (Prohaska and Wells, 1974). Severely copper-deficient
mice, with a knock-out of the Ctr1 gene, exhibit growth, and
viability defects which can be partially rescued by postnatal cop-
per administration (Nose et al., 2006). The neurological effects
of copper deficiency during perinatal life strongly depends on
the timing of the deficiency, suggesting a critical period for brain
copper acquisition (Prohaska and Brokate, 2001). An increase in
the copper concentration between P7 and P14 was observed in
the striatum, thalamus, and superior colliculus in rats (Tarohda
et al., 2005). Copper deficiency in adult humans leads to ascending
sensory tract dysfunction and neurodegeneration of the sensory
dorsal column resulting in myelopathy accompanied by spastic-
ity and sensory ataxia. Copper supplementation prevents further
neurologic deterioration in such patients, but the degree of actual
improvement is variable (Kumar et al., 2004; Prodan et al., 2006).
INHERITED DISEASES THAT LEAD TO IMPAIRED MANAGEMENT OF
COPPER IN THE BRAIN
Menkes disease is caused by a mutation in the gene encoding the
copper transporter ATP7A that results in severe copper deficiency
in the brain. Affected individuals display psychomotor deteriora-
tion, neuronal loss, demyelination, and neurodegeneration in the
gray matter of the brain (Okeda et al., 1991; Kaler, 1998; Kodama
et al., 1999) and individuals with the classical severe form of
Menkes disease die within the first 3 years of life. ATP7A is required
to facilitate copper transport across the BBB (Qian et al., 1998),
and the neurological characteristics of Menkes disease are present
in early infancy and emphasize a critical role of copper in neu-
ronal development. In Menkes disease patients with some residual
and functional ATP7A, less neurological pathology is observed. In
these patients copper therapy can improve the neurological symp-
toms (Kaler et al., 1995; Christodoulou et al., 1998; Moller et al.,
2000).
Wilson disease is caused by a mutation in the gene encod-
ing the copper transporter, ATP7B, which is primarily expressed
in the liver, but also in the brain (Saito et al., 1999). The main
symptoms of Wilson disease are hepatic copper accumulation,
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copper-mediated liver damage, leakage of copper into the plasma,
and subsequent copper-overload in all tissues, including the brain
(Gitlin, 2003; Tao and Gitlin, 2003). Brain copper accumulation
leads to symptoms such as dystonia, psychiatric symptoms of
depression, cognitive deterioration, personality change, schizo-
phrenia, psychosis, and Parkinsonian symptoms (Oder et al., 1991;
Ferenci, 2004). Almost half of all Wilson disease patients display
symptoms of neuropsychiatric illness (Gollan and Gollan, 1998).
However, the symptoms can be reversed by the administration
of copper-chelating agents to the Wilson disease patient (Brewer
et al., 2003, 2006). ATP7B is important for the delivery of copper
to ceruloplasmin in the liver. The function of ATP7B in the brain is
unknown, but it can be hypothesized that ATP7B also is involved
in the delivery of copper to ceruloplasmin in the brain (see below).
Aceruloplasminemia is an autosomal recessive disorder of iron
metabolism, caused by loss-of-function mutations in the gene
encoding ceruloplasmin and with an adult-onset. Ceruloplasmin
is a ferroxidase, which oxidizes ferrous iron to ferric iron, and a
trinuclear cluster of copper is essential for the activity of ceru-
loplasmin. Ceruloplasmin is mainly expressed in the liver, but
also in cells in the brain such as astrocytes and epithelial cells
in the choroid plexus (Klomp and Gitlin, 1996; Klomp et al.,
1996). The disease results in systemic symptoms such as decreased
serum iron levels, elevated serum ferritin, anemia, and increased
levels of non-transferrin bound iron, and neurological symp-
toms, such as progressive dementia, dystonia, neuronal cell loss,
and excess iron accumulation in glia and neurons (Logan et al.,
1994; Morita et al., 1995; Oide et al., 2006). The ceruloplasmin
form expressed in astrocytes is attached to the cell surface by
a glycosyl-phosphatidylinositol (GPI) anchor (Patel and David,
1997). Astrocytes in ceruloplasmin-deficient mice have a decreased
ability to release iron from neurons (Jeong and David, 2003). The
mechanism behind this effect is unknown, but might be due to a
transfer of the GPI-anchored ceruloplasmin from the astrocytes
to the neurons (Jeong and David, 2003). Accordingly, aceruloplas-
minemia leads to accumulation of iron in the brain, which explains
many of the neurological symptoms mentioned above.
NEURODEGENERATIVE DISORDERS ASSOCIATED WITH IMPAIRED
COPPER METABOLISM IN THE BRAIN
Alzheimer’s disease is characterized by progressive neuronal
degeneration, memory impairment, dementia, progressive decline
in cognitive function, and volume loss in the telencephalon. It
also leads to the formation of senile plaques that mainly con-
sist of the amyloid beta peptides (generated from APP) and the
formation of neurofibrillary tangles from abnormal tau proteins
(Caselli et al., 2006; Kelley and Petersen, 2007). The involvement of
copper in Alzheimer’s disease is not clear, as some studies show ele-
vated serum-copper levels in Alzheimer’s disease patients (Squitti
et al., 2006; Arnal et al., 2010), whereas others fail to find dif-
ferences in copper levels when compared to controls (Ozcankaya
and Delibas, 2002; Gerhardsson et al., 2008). Some studies even
find decreased levels of copper in blood samples of Alzheimer’s
disease patients (Brewer et al., 2010; Vural et al., 2010). A meta-
analysis study performed on studies carried out from 1983 to 2010
showed that Alzheimer’s disease patients (761 individuals) gen-
erally have slightly higher levels of serum-copper than healthy
controls (664 individuals; Bucossi et al., 2011b). However, no dif-
ference was observed in CSF-copper levels (116 Alzheimer’s disease
patients and 126 healthy controls). Notably, both the aggregation
and neurotoxicity of Aβ depend on the presence of copper. Fur-
thermore, APP plays a role in regulation of cellular copper export.
Several studies have shown that over-expression of APP leads to
decreased copper in yeast (Treiber et al., 2004) and in brains of
mice (Maynard et al., 2002). That copper metabolism is involved
in the pathogenesis of Alzheimer’s disease is however, emphasized
as several polymorphisms in the gene encoding the copper trans-
porter ATP7B seem to be linked to the development of Alzheimer’s
disease. Several single nucleotide polymorphisms (SNPs) in the
ATP7B gene have been shown to increase the relative risk of devel-
oping Alzheimer’s disease by up to 82% (Bucossi et al., 2011a,
2012).
Several studies have also demonstrated a connection between
copper accumulation and the pathogenesis of Parkinson’s disease.
The total copper content is reduced in the substantia nigra com-
pacta and caudate nucleus in Parkinson’s disease patients (Dexter
et al., 1989; Loeffler et al., 1996). The administration of copper is, to
some extent, neuroprotective against dopaminergic degeneration.
INTERACTIONS IN THE HANDLING OF IRON AND COPPER IN
THE BRAIN
INTERACTION BETWEEN COPPER AND IRON METABOLISM IN DIETARY
CHALLENGES
Many studies have demonstrated an interaction between copper
and iron after challenges to their dietary availability levels (Pro-
haska and Wells, 1974; Penland and Prohaska, 2004). An overview
of reported effects is shown in Table 2. Dietary deficiency of either
copper or iron leads to anemia and a higher liver concentration of
the other metal (Pyatskowit and Prohaska, 2008). Copper and iron
interact at the molecular level, e.g., copper binds to and regulates
the activity of the IRP, which is a regulator of expression of multi-
ple proteins involved in iron metabolism as described previously.
It is known that the level of iron regulates the binding capacity of
the IRP to the IRE. Interestingly, copper also mediates decreased
binding of IRE/IRP by direct binding of the metal to IRP at the
site, which also binds iron (Oshiro et al., 2002).
The response of IRP to copper is similar to the response to
iron (Garrick et al., 2003b). The effect of copper on the IRP/IRE
binding is emphasized by an approximately 55% decreased mRNA
expression of the transferrin receptor in response to high cop-
per concentrations in vitro (Oshiro et al., 2002). Human PCL
hepatoma cells were in this study exposed to 150µM copper, which
is higher than in normal human serum. However, in pathophysio-
logical conditions levels of 200µM serum-copper and higher has
been reported (Song et al., 2009). Furthermore, studies of Caco-2
cells have shown that excess copper results in a decreased mRNA
and protein expression of the DMT1-isoform containing an IRE,
and an increased expression of the iron exporter ferroportin (Ten-
nant et al., 2002). Concurrent with the increased expression of
ferroportin, a 40% increase in iron efflux from the Caco-2 cells
was seen (Tennant et al., 2002). Furthermore, both copper and
iron are transported with high efficiency by DMT1 as shown in
in vitro assays (Garrick et al., 2003a). Notably, it has been shown
in knockdown studies on immortalized choroid cells (Z310), that
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Table 2 | Effect of high or low systemic levels of metal 1 on the level of
metal 2 in the brain and on transporters of metal 2.
Systemic level
of metal 1
Effect on brain
level of metal 2
Effect on transporters
of metal 2
Iron ↓ Copper transport↑ ATOX1 ↑
Copper in CSF ↑ ATP7A ↑
Brain parenchyma↑
Choroid plexus↑
Iron ↑ Copper transport ↓ DMT1 (+IRE)↓
Copper in CSF ↓ TfR ↓
Brain parenchyma↑
Choroid plexus↑
Ferroportin↑
Copper ↓ Iron ↓(short term) Hephestin↓
Iron ↑ (long term) GPI-ceruloplasmin↓
Copper ↑ Iron ↓ DMT1 (+IRE)↓
TfR ↓
Ferroportin↑
Copper↑+ Iron ↑ Copper↑
Iron ↑
Metal 1 is iron or copper, respectively. Metal 2 is the opposite metal, copper or
iron, respectively. TfR, transferrin receptor.
Ctr1 is the main transporter of copper over DMT1 (Zheng et al.,
2012). However, in cells where DMT1 is located to the cell mem-
brane, as in duodenal enterocytes and epithelial cells of the choroid
plexus, there is a coupling between copper and iron homeostasis.
The interaction between the copper and iron homeostasis appa-
ratus has been demonstrated in vitro on choroid epithelial cells,
BCB Z310. In response to iron deficiency, the expression of DMT1
mRNA as well as the dedicated copper transporters ATOX1 and
ATP7A is upregulated, whereas there is no change in the expression
levels of Ctr1 (Monnot et al., 2012). The same regulatory picture
is seen in vivo in duodenum, where the expression of DMT1 and
ATP7A, but not of Ctr1 or ATP7B, is strongly induced in rat duo-
denum in response to dietary iron deficiency; significantly higher
liver-copper levels were additionally observed (Collins et al., 2005).
Concordantly, iron-deficient rats display a significantly higher rate
of copper clearance from the CSF as compared to controls and
copper overloaded animals (Monnot et al., 2011). The effect of
iron deficiency on copper export and ATP7A might be attrib-
uted to increased transcription levels. Recent results have shown
that ATP7A is upregulated by the transcription factor hypoxia
inducible factor (HIF2alpha) in response to iron deficiency in rat
intestinal epithelia (Xie and Collins, 2011), which could also be
the case in the brain.
EFFECT OF ABNORMAL COPPER LEVELS ON THE LEVEL OF IRON
Both copper deficiency and excess lead to altered iron homeostasis
in the brain. For instance, in rats which are fed a copper-rich diet,
the iron uptake in the brains of P15 and P63 rats is significantly
lower than in controls (Crowe and Morgan, 1996). However, dual
administration of iron and copper in the diet results in an increase
in both metals in the brain (Crowe and Morgan, 1996).
Copper deficiency was shown to confer 49% reduction in
plasma iron levels but unchanged brain iron levels in P50 rats
after 30 days on a postnatal copper-deficient diet (Prohaska and
Gybina, 2005). The low serum iron is probably due to impaired
transport of iron from the duodenum to the circulation as a result
of decreased activity of hephestin which is essential for the cellular
iron export function of ferroportin (Umbreit, 2005). Iron uptake
of the brain is supposedly independent of proenzymes contain-
ing copper, as described previously, which is concordant with no
effect on brain iron levels in the copper-deficient rats. Brain cop-
per levels were 37% reduced in the copper-deficient P50 rats and
it can be speculated that over time the copper deficiency may lead
to brain iron accumulation, as seen in pathological conditions
like aceruloplasminemia, which has an adult-onset at the age of
45–55. The symptoms in aceruloplasminemia are caused by CNS
iron accumulation due to defects in ceruloplasmin as described.
GPI-anchored ceruloplasmin in astrocytes is vital for iron release
from these iron storage cells. Copper deficiency has been shown
to lead to lower GPI-anchored ceruloplasmin in spleen and liver
of mice and rats, and the same may be the case for astrocytic GPI-
anchored ceruloplasmin (Mostad and Prohaska, 2011). Increased
turnover rate is suggested to be the reason for the decreased pro-
tein levels. Other copper-containing proteins are essential in iron
metabolism and may lead to accumulation of iron due to copper
deficiency, e.g., hephestin as the activity of this protein is vital for
iron export via ferroportin. Ferroportin is abundantly expressed in
the epithelial cells of the choroid plexus, which in turn is involved
in iron transport out of the CNS and into the circulation. Hence,
a decline in hephestin activity probably would contribute to iron
accumulation in the brain during copper deficiency.
In rats perinatal copper deficiency leads to decreased plasma
and brain iron levels (Prohaska and Gybina, 2005; Pyatskowit and
Prohaska, 2008). Interestingly, varying results have been obtained
in mice as one study finds unchanged plasma and brain iron levels
when copper-deficient (Pyatskowit and Prohaska, 2008), whereas
others report decreased plasma and iron levels in similarity to
observations in the rat. Age and strain differences may explain the
differing results. Human infants with copper deficiency have lower
plasma iron levels and it is speculated that brain iron levels may
also be low (Pyatskowit and Prohaska, 2008).
Prohaska and Gybina hypothesize that the observed iron defi-
ciency pups from copper-deficient dams could be due to impaired
transport of iron across the placenta, as it has been known that
copper deficiency inhibits iron transport in placental BeWo cells
in vitro (Danzeisen et al., 2002). It has been suggested that this phe-
nomenon might be attributed to the lack of ferroxidase activity of a
vital ceruloplasmin homolog which was identified in rat placenta
cells and shown to have a lower level of activity and expression
under copper-deficient conditions (Danzeisen et al., 2002). This
ferroxidase may be zyklopen, which has high sequence identity
to hephestin and ceruloplasmin but a distinct expression pattern.
Zyklopen is expressed in placenta and in mammary glands, and
the protein level is decreased in cellular copper deficiency (Chen
et al., 2010). In the suckling pup, low iron levels are maintained as
the iron content in milk is additionally lower in copper-deficient
rats (Prohaska, 1989), which may also be due to altered activity
of zyklopen. Thus, these results emphasize that adequate dietary
copper in dams is necessary for adequate iron transfer to pups,
which in turn, is crucial for brain development.
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EFFECT OF ABNORMAL IRON LEVELS ON THE LEVEL OF COPPER
Both iron deficiency and overload lead to altered copper home-
ostasis in the brain. An in vivo study on adult rats showed that
iron-deficient rats had a 92% increase in copper transport into
the brain, and significantly elevated copper levels in the CSF, brain
parenchyma, and choroid plexus, although the plasma copper lev-
els were normal (Monnot et al., 2011). A significant increase in
brain copper levels has also been shown in pups due to perina-
tal iron deficiency (Bastian et al., 2010). Iron-overloaded rats, in
contrast, have been shown to have lower plasma copper levels, a
56% decrease in copper transport into the brain, and lower cop-
per levels in the CSF. Interestingly, a modest increase of copper
levels in brain parenchyma and choroid plexus was observed in
the iron-overloaded animals (Monnot et al., 2011). The authors
hypothesize that the observed increase in copper in the brain
parenchyma and the choroid plexus in the iron-overloaded ani-
mals might be attributed to an increased demand for copper for the
production of ceruloplasmin and hephestin to export excess iron.
The higher transport of copper into the iron-deficient brain is not
accompanied by a correspondingly higher uptake of ceruloplasmin
(Crowe and Morgan, 1996).
OUTLOOK
The uptake of iron at the BBB is well documented when the avail-
ability of an appropriate diet varies, but its subsequent transport
into the brain needs further attention. The putative absence of
DMT1 in brain capillary endothelial cells is congruous with a tran-
scytotic transport of holotransferrin, but confusingly there is no
real evidence for the transport of transferrin across the BBB. Stud-
ies have failed to identify ferroportin in brain capillary endothelial
cells. With regard to the transport of copper at the BBB, the evi-
dence points to uptake by Ctr1. There is no luminally expressed
DMT1 that could account for the uptake of low-molecular weight
copper at the BBB. Copper circulates in the blood plasma bound
to proteins like ceruloplasmin and albumin, but the mechanism by
which these proteins could donate copper at the BBB is not clear.
The roles of transferrin and ceruloplasmin secreted by the
choroid plexus epithelial cells in iron homeostasis, in terms
of extracellular binding and donation to receptor-containing
neurons and ferroxidase activity by astrocytes respectively, are still
unexplained. More research is needed to elucidate the possible
transport of transferrin and ceruloplasmin from the ventricular
system to the brain interstitium.
Iron levels in the brain are clearly reflected in the expression
patterns of transferrin receptors and ferritin in neurons. Iron is
thought to contribute significantly to the deleterious outcome of
acute and chronic lesions in the brain. The role of iron in these
conditions is far from resolved. In spite of a consistent expres-
sion of ferroportin by neurons, there is no real information on
whether neurons are capable of exporting iron to the cellular exte-
rior. More knowledge about these processes will probably add
significantly to the understanding of how iron can cause dam-
age to neurons, and probably also to the identification of putative
pharmaceutical targets to improve neuronal iron-handling. The
molecules that transport copper inside the brain to uptake in neu-
rons and glia are not well documented. In contrast to iron that
accumulates in neurons in neurodegenerative diseases, the level of
copper seems to decrease, suggesting that neurons are capable of
excreting copper.
We are far from understanding how iron and copper together
are handled by neurons and glia when changes in the availability
of these metals occur. Experimental models using animals with
loss-of-function mutations that affect single proteins will reveal
more information on these matters.
Handling iron- or copper- deficiencies is manageable with
oral or parenteral supplementations. More sophisticated strate-
gies, e.g., genetic therapy will be needed to treat single-mutation
diseases known to affect iron and copper levels in the brain. The
use of chelators to treat conditions with robust accumulation of
iron or copper will benefit from more knowledge on the site of
action of the chelating drugs as the homeostasis in overload con-
ditions often derives from metal-accumulation in single cell types
in the brain.
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